Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1552
Peer-review started: November 27, 2021
First decision: January 23, 2022
Revised: January 19, 2022
Accepted: July 26, 2022
Article in press: July 26, 2022
Published online: August 15, 2022
Processing time: 256 Days and 7.7 Hours
Duodenal-type follicular lymphoma (D-FL) has been recognized as a rare entity that accounts for approximately 4% of primary gastrointestinal lymphomas. D-FL follows an indolent clinical course compared with common nodal FL and is generally considered to have a better prognosis. Therefore, the “watch and wait” approach is frequently adopted as the treatment method. Alternatively, there is an option to actively intervene in D-FL. However, the long-term outcomes of such cases are poorly understood.
To clarify the clinical outcomes after long-term follow-up in cases of D-FL with treatment intervention.
We retrospectively analyzed patients who met the following criteria: the lesion was confirmed by endoscopy, the diagnosis of D-FL was confirmed histopathologically, and the patient was followed-up for more than 10 years after the intervention at our center.
We identified 5 cases of D-FL. Two patients showed a small amount of bone marrow involvement (Stage IV). Rituximab was used as a treatment for remission in all 5 patients. It was also used in combination with chemotherapy in 2 Stage IV patients as well as for maintenance treatment. Radiation therapy was performed in 2 cases, which was followed by complete remission (CR). Eventually, all 5 patients achieved CR and survived for more than 10 years. However, 3 patients experienced recurrence. One patient achieved a second CR by retreatment, and in another case, the lesion showed spontaneous disappearance. The remaining patient had systemic widespread recurrence 13 years after the first CR. Biopsy results suggested that the FL lesions were transformed into diffuse large B-cell lymphoma. The patient died 4 years later despite receiving various chemotherapies.
In this study, the treatment for patients of D-FL in Stage IV was successful. In the future, criteria for how to treat “advanced” D-FL should be established based on additional cases. This study of patients with D-FL indicates that whole-body follow-up examinations should continue for a long time due to a fatal recurrence 13 years after reaching CR.
Core Tip: Since duodenal-type follicular lymphoma (D-FL) progresses more indolently than common nodal FL, the “watch and wait” approach is frequently used without intervention. To elucidate the clinical assessments of long-term follow-up in cases of D-FL with treatment intervention, we retrospectively examined 5 D-FL patients for more than 10 years after treatment at our center. All 5 patients eventually achieved complete remission and survived for a long period. However, 3 patients experienced recurrence, and 1 patient died of the primary disease 21 years after first onset. In the future, it will be necessary to establish criteria for how to treat Stage IV “advanced” D-FL.